- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Progestogen-only pill.
Displaying page 1 of 1.
EudraCT Number: 2013-000357-41 | Sponsor Protocol Number: APC040 | Start Date*: 2013-08-28 |
Sponsor Name:The Alimentary Pharmabiotic Centre, University College Cork | ||
Full Title: Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients | ||
Medical condition: Irritable Bowel Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-000550-12 | Sponsor Protocol Number: NRL920-01/2008 (IBSc) | Start Date*: 2008-11-06 | |||||||||||
Sponsor Name:Norgine Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® with Placebo in Patients with Constipation Associated... | |||||||||||||
Medical condition: Constipation associated with Irritable Bowel Syndrome (IBS-C). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002955-85 | Sponsor Protocol Number: AVICCI001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment. The AVICCI study | |||||||||||||
Medical condition: Human Immunodeficiency Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001934-16 | Sponsor Protocol Number: AMZ001-006 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Amzell BV | |||||||||||||
Full Title: A placebo-controlled, double-blind, randomized, trial of Diclofenac Gel AMZ001 3.06 % for the treatment of knee osteoarthritis symptoms | |||||||||||||
Medical condition: Knee Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000100-37 | Sponsor Protocol Number: V01-126A-202 | Start Date*: 2022-01-03 | |||||||||||
Sponsor Name:Bausch Health Americas, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treat... | |||||||||||||
Medical condition: Acne Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003124-16 | Sponsor Protocol Number: KH176-204 | Start Date*: 2021-01-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. | ||
Medical condition: Genetically confirmed mitochondrial disease | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007420-26 | Sponsor Protocol Number: D9127C00002 | Start Date*: 2009-05-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sens... | |||||||||||||
Medical condition: Gastroesophageal Reflux Disease (GERD) is the intended indication | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004448-12 | Sponsor Protocol Number: ARQ087-301 | Start Date*: 2017-12-18 | ||||||||||||||||
Sponsor Name:ARQULE INC | ||||||||||||||||||
Full Title: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma | ||||||||||||||||||
Medical condition: Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IE (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013792-22 | Sponsor Protocol Number: LEO 29102-C21 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:LEO Pharma A/S | |||||||||||||
Full Title: A Phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel (Pim... | |||||||||||||
Medical condition: Diagnosis of atopic dermatitis graded as mild to moderate according to the Rajka and Langeland system. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000832-23 | Sponsor Protocol Number: KH176-203 | Start Date*: 2021-07-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutatio... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002081-39 | Sponsor Protocol Number: CLI/22 | Start Date*: 2019-03-14 | |||||||||||
Sponsor Name:Abiogen Pharma S.p.A. | |||||||||||||
Full Title: A randomised, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study, to evaluate the efficacy and safety of clodronate ampoules at different dosages, after intra-articul... | |||||||||||||
Medical condition: knee osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002945-39 | Sponsor Protocol Number: CM-101-PSC-101 | Start Date*: 2020-04-15 | |||||||||||
Sponsor Name:ChemomAb Ltd | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004639-26 | Sponsor Protocol Number: LX9211.1-202-PHN | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1) | |||||||||||||
Medical condition: Postherpetic Neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000599-40 | Sponsor Protocol Number: KH176-202 | Start Date*: 2019-10-23 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirme... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004534-38 | Sponsor Protocol Number: C928-011 | Start Date*: 2021-10-11 | |||||||||||
Sponsor Name:DURECT Corporation | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis | |||||||||||||
Medical condition: Alcoholic hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003358-25 | Sponsor Protocol Number: PC10VAC02 | Start Date*: 2013-11-25 | |||||||||||
Sponsor Name:Genticel | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL | |||||||||||||
Medical condition: Women infected by HPV 16 and/or HPV 18 with normal cytology or ASCUS/LSIL | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) FI (Completed) DE (Completed) NL (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005012-42 | Sponsor Protocol Number: 747-302 | Start Date*: 2016-01-05 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
